ReviewJournal of cardiovascular development and disease2026
Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.
Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the last decade, immunotherapy has transformed oncology, with an ever-expanding list of indications. As with any therapeutic class, these agents are accompanied by adverse events that are increasingly recognized and pose new challenges for patient care expanding the scope of cardio-oncology. Using the PubMed database, this narrative review summarizes the cardiovascular adverse events associated with the most commonly used immunotherapies, immune checkpoint inhibitors (ICIs), with a focus on the mechanisms, epidemiology, diagnosis, treatment, and monitoring of ICI-associated myocarditis. We also review accelerated atherosclerotic disease, heart failure, cardiomyopathy (including stress-induced cardiomyopathy), arrhythmias, and pericardial disease related to ICI therapy. Finally, we outline CAR T-cell therapy associated cardiotoxicity, including cytokine release syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.